| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Pacifici GM | |
| P2860 | cites work | Ceftizoxime disposition in neonates and infants during the first six months of life | Q30447980 |
| Evaluation of a potential clinical interaction between ceftriaxone and calcium | Q33768920 | ||
| Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. | Q33826426 | ||
| Population pharmacokinetics of cefepime in the neonate | Q33883677 | ||
| Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children | Q35137735 | ||
| Pharmacokinetics of cefotaxime in newborn infants | Q35675362 | ||
| Cefoperazone pharmacokinetics in preterm infants | Q35740042 | ||
| Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration | Q35755881 | ||
| Vancomycin: pharmacokinetics and administration regimens in neonates | Q35771508 | ||
| Pathophysiologic basis for the use of third-generation cephalosporins | Q37915952 | ||
| Clinical pharmacokinetics of antibacterial drugs in neonates | Q37956835 | ||
| Classification of cephalosporins. | Q39685294 | ||
| Once-daily versus twice-daily administration of ceftazidime in the preterm infant | Q39780414 | ||
| Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime | Q39835738 | ||
| Pharmacokinetics of ceftazidime in newborn infants | Q39849134 | ||
| Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy | Q40219455 | ||
| Third-generation cephalosporins | Q40550719 | ||
| Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics | Q41461666 | ||
| Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin | Q41763473 | ||
| Pharmacokinetics of cefoperazone in full-term and premature neonates | Q41892422 | ||
| Pharmacokinetics and clinical efficacy of cefuroxime in the newborn period | Q42007546 | ||
| Pharmacokinetics of Ceftriaxone in Pediatric Patients With Meningitis | Q42177357 | ||
| Ceftriaxone pharmacokinetics in newborn infants | Q42275231 | ||
| Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts | Q44848659 | ||
| Population pharmacokinetics of cefepime in neonates with severe nosocomial infections. | Q46614990 | ||
| Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates | Q47173774 | ||
| In-vitro activity of ceftazidime, a beta-lactamase stable cephalosporin | Q50215977 | ||
| The in-vitro activity of ceftazidime compared with that of other cephalosporins | Q50215980 | ||
| Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. | Q54364960 | ||
| Pharmacokinetics of ceftizoxime | Q67256936 | ||
| Pharmacokinetics of cefotaxime in preterm infants | Q68724580 | ||
| Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of 'free' bilirubin and erythrocyte-bound bilirubin | Q69138781 | ||
| Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis | Q69904042 | ||
| Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate | Q70141515 | ||
| Pharmacokinetics of cefoperazone in newborn infants | Q70656595 | ||
| Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age | Q70806299 | ||
| Cefoxitin in newborn infants. A clinical and pharmacokinetic study | Q71142491 | ||
| Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates | Q72402147 | ||
| Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study | Q72840540 | ||
| Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis | Q80140100 | ||
| Pharmacokinetics and safety of ceftriaxone in the neonate | Q93659356 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney | Q9377 |
| amides | Q188777 | ||
| pharmacokinetics | Q323936 | ||
| genitourinary system | Q4712977 | ||
| heterocyclic compound | Q193430 | ||
| antibiotic | Q12187 | ||
| P304 | page(s) | 1267-74 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Clinics | Q26841864 |
| P1476 | title | Pharmacokinetics of cephalosporins in the neonate: a review | |
| P478 | volume | 66 |
| Q37358644 | A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants |
| Q38546483 | Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis |
| Q40064762 | Antimicrobial drug-related problems in a neonatal intensive care unit |
| Q36069519 | Cefepime and Ceftazidime Safety in Hospitalized Infants |
| Q57800926 | Ceftriaxone absorption enhancement for noninvasive administration as an alternative to injectable solutions |
| Q38975534 | Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. |
| Q90210744 | Drugs for the Prevention and Treatment of Sepsis in the Newborn |
| Q35532010 | High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination |
| Q64981487 | The consequences of prolonged duration of antibiotics in premature infants with suspected sepsis in a large tertiary referral hospital: a retrospective cohort study. |
| Q38161817 | The interplay between drugs and the kidney in premature neonates. |
Search more.